Publication
Anticancer effects of an XPO1 inhibitor (selinexor) with sotorasib following omeprazole preconditioning in KRAS G12C-mutant non-small cell lung cancer cells in vitro and in a mouse tumor xenograft.
Jèssica González, Xueting Cai, Wenjing Diao, Gaël Roué, Kevin València-Clua, Daniel Olmo-González, María González-Cao, Anisha Jain, Eloisa Jantus-Lewintre, Ana Giménez-Capitán, Miguel Angel Molina-Vila, Jordi Codony-Servat, Peng Cao, Rafael Rosell
- Source
- PubMed
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260911-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC) is currently treated with KRAS G12C covalent inhibitors, such as sotorasib, or RAS (ON) G12-selective inhibitors; however, response rates and progression-free survival remain limited, with recurrence occurring in most…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Lung Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available